A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Active:	Yes
Cancer Type:	Lung Cancer Neuroendocrine Tumor Unknown Primary	NCT ID:	NCT07037758
Trial Phases:	Phase I	Protocol IDs:	20240200 (primary) NCI-2025-06049
Eligibility:	18 - 90 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Amgen, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT07037758

Summary

The primary objective for dose exploration and dose expansion is to evaluate the safety
and tolerability of tarlatamab in combination with AB248.

The primary objective for dose exploration only is to determine the recommended dose for
expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with
tarlatamab.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.